Live Breaking News & Updates on Codebreak 200 Trial

Stay updated with breaking news from Codebreak 200 trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Issues Complete Response Letter to Sotorasib for KRAS G12C–Mutated NSCLC

The FDA has issued a complete response letter to the supplemental new drug application seeking the full approval of sotorasib for patients with KRAS G12C–mutated non–small cell lung cancer. ....

United States , Full Approval Of Sotorasib , Patients With Kras G12c Mutated Non Small Cell Lung Cancer , Codebreak 200 Trial , Codebreak 100 Trial ,

Sotorasib Provides Consistent Clinical Benefit Over Docetaxel in Key Co-Alteration Subgroups of KRAS G12C+ NSCLC

Sotorasib provided consistent benefit over docetaxel in the majority of key prespecified molecularly defined subsets of patients with pretreated KRAS G12C–mutated non–small cell lung cancer enrolled to the phase 3 CodeBreaK 200 trial. ....

United States , Sotorasib Lumakras , Ferdinandos Skoulidis , Department Of Thoracic Head , University Of Texas Md Anderson Cancer Center , Neck Medical Oncology , Cancer Center , Kras G12c , Non Small Cell Lung Cancer , Asco Annual Meeting , Codebreak 200 Trial ,